Page 41 - Read Online

Armengol et al. Hepatoma Res 2021;7:50 https://dx.doi.org/10.20517/2394-5079.2021.19 Page 11 of 12

24. Vokuhl C, Oyen F, Haberle B, von Schweinitz D, Schneppenheim R, Leuschner I. Small cell undifferentiated (SCUD)
hepatoblastomas: all malignant rhabdoid tumors? Genes Chromosomes Cancer 2016;55:925-31. DOI PubMed
25. Zhou S, Venkatramani R, Gupta S, et al. Hepatocellular malignant neoplasm, NOS: a clinicopathological study of 11 cases from a
single institution. Histopathology 2017;71:813-22. DOI PubMed PMC
26. Cairo S, Armengol C, Maibach R, et al. A combined clinical and biological risk classification improves prediction of outcome in
hepatoblastoma patients. Eur J Cancer 2020;141:30-9. DOI PubMed
27. Carrillo-Reixach J, Torrens L, Simon-Coma M, et al. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with
clinical implications. J Hepatol 2020;73:328-41. DOI PubMed
28. Jeong Y, Hellyer JA, Stehr H, et al. Role of KEAP1/NFE2L2 Mutations in the chemotherapeutic response of patients with non-small
cell lung cancer. Clin Cancer Res 2020;26:274-81. DOI PubMed PMC
29. Jia D, Dong R, Jing Y, et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and
ubiquitin ligase complex. Hepatology 2014;60:1686-96. DOI PubMed
30. Lee H, El Jabbour T, Ainechi S, et al. General paucity of genomic alteration and low tumor mutation burden in refractory and
metastatic hepatoblastoma: comprehensive genomic profiling study. Hum Pathol 2017;70:84-91. DOI PubMed
31. Cairo S, Wang Y, de Reynies A, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad
Sci U S A 2010;107:20471-6. DOI PubMed PMC
32. Hooks KB, Audoux J, Fazli H, et al. New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. Hepatology
2018;68:89-102. DOI PubMed
33. Cui X, Liu B, Zheng S, Dong K, Dong R. Genome-wide analysis of DNA methylation in hepatoblastoma tissues. Oncol Lett
2016;12:1529-34. DOI PubMed PMC
34. Honda S, Minato M, Suzuki H, et al. Clinical prognostic value of DNA methylation in hepatoblastoma: four novel tumor suppressor
candidates. Cancer Sci 2016;107:812-9. DOI PubMed PMC
35. Maschietto M, Rodrigues TC, Kashiwabara AY, et al. DNA methylation landscape of hepatoblastomas reveals arrest at early stages of
liver differentiation and cancer-related alterations. Oncotarget 2017;8:97871-89. DOI PubMed PMC
36. Buj R, Mallona I, Diez-Villanueva A, et al. Quantification of unmethylated Alu (QUAlu): a tool to assess global hypomethylation in
routine clinical samples. Oncotarget 2016;7:10536-46. DOI PubMed PMC
37. Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's
Hepatic tumors International Collaboration. Lancet Oncol 2017;18:122-31. DOI PubMed PMC
38. Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976;67:1-10. PubMed
39. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. Characterization of the continuous cell line HepT1
derived from a human hepatoblastoma. Lab Invest 1996;74:809-18. PubMed
40. Hartmann W, Waha A, Koch A, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a
comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 2000;157:1393-403. DOI PubMed PMC
41. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-
derived cell line. Nature 1979;282:615-6. DOI PubMed
42. Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB. Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol 2009;40:1512-
5. DOI PubMed
43. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B
surface antigen. Science 1980;209:497-9. DOI PubMed
44. Hartmann W, Kuchler J, Koch A, et al. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma
survival. Clin Cancer Res 2009;15:4538-45. DOI PubMed
45. Eriksson T, Frisk T, Gray SG, et al. Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary
tumor, established cell line, and xenograft of a human hepatoblastoma. Exp Cell Res 2001;270:88-95. DOI PubMed
46. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary
tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26:611-21. DOI PubMed
47. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:
involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35. DOI PubMed
48. Wagner F, Henningsen B, Lederer C, et al. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment
options in high-risk patients. Eur J Cancer 2012;48:2442-50. DOI PubMed
49. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-
dependent mechanism. Oncogene 2007;26:1932-40. DOI PubMed
50. Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B, Ganschow R. The use of everolimus in pediatric liver transplant
recipients: first experience in a single center. Pediatr Transplant 2011;15:510-4. DOI PubMed
51. Eichenmüller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009;49:482-
90. DOI PubMed
52. Huang S, He J, Zhang X, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis
2006;27:1334-40. DOI PubMed
53. Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005;8:5-6. DOI PubMed
54. Lieber J, Kirchner B, Eicher C, et al. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr
Blood Cancer 2010;55:1089-95. DOI PubMed
55. Lieber J, Eicher C, Wenz J, et al. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.